Source:European Journal of Surgical Oncology (EJSO)
Author(s): Tiziana Comito, Luca Cozzi, Alessandro Zerbi, Ciro Franzese, Elena Clerici, Angelo Tozzi, Cristina Iftode, Pierina Navarria, Giuseppe D'Agostino, Antonella Fogliata, Pietro Mancosu, Stefano Tomatis, Carlo Carnaghi, Nicola Personeni, Armando Santoro, Marta Scorsetti
ObjectiveTo evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery.MethodsA retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.ResultsBetween January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91% and 82% at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI >18 months. No cases of acute G3 toxicity or greater occurred.ConclusionsSBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.
http://ift.tt/2jvUKpo
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου